

Little Folk Stroke: Current Questions

S.G. Pavlakis and G. deVeber

Newborn Brain Infarction: Clinical Aspects and Magnetic Resonance Imaging

A. Venkataraman, P.B. Kingsley, P. Kalina, S.G. Pavlakis, S. Buckwald, R. Spinazzola, and R. Harper

Risk Factors for Arterial Ischemic Stroke in Childhood

F.J. Kirkham and A.M. Hogan

Recovery After Acquired Stroke in Childhood

R.D. Nass and D. Trauner

Sickle Cell Disease: Primary Stroke Prevention

M. Gebreyohanns and R.J. Adams

Health-Related Quality of Life and Its Relationship to Neurological Outcome in Child Survivors of Stroke

S. Friefeld, O. Yeboah, J.E. Jones, and G. deVeber

Decision Analysis of Cost-Effectiveness of Repetitive Transcranial Magnetic Stimulation Versus Electroconvulsive Therapy for Treatment of Nonpsychotic Severe Depression

F.A. Kozel, M.S. George, and K.N. Simpson

Index Medicus/MEDLINE citation: CNS Spectr



In the management of ADHD,

reveal his

potential

ADDERALL XR[®] Improves Academic Performance¹⁻⁴

- Objective measures of academic performance improved significantly throughout the day^{1,2}
- Patients completed 26 more math problems *correctly**

*Averaged throughout a 12-hour day and compared with placebo in a crossover design study.^{1,2}

The most common adverse events include loss of appetite, insomnia, abdominal pain, and emotional lability.

As with other psychostimulants indicated for ADHD, there is a potential for exacerbating motor and phonic tics and Tourette's syndrome. A side effect seen with the amphetamine class is psychosis. Caution also should be exercised in patients with a history of psychosis.

with two-sided improvement

ADDERALL XR Enhances Social Functioning⁵


- Helps provide efficacy that lasts through school and other social activities¹⁻⁴
- Significantly improves *attention* and *behavior* throughout the school day and into the early evening¹⁻⁴

Please see references and brief summary of prescribing information on adjacent bage.

www.ADDERALLXR.com

Shire US Inc. ur ADHD sup 100-828-2088

©2003 Shire US Inc., Newport, Kentucky 41071



AXIA333

Abuse of amphetamines may lead to dependence. ADDERALL XR is contraindicated in patients with symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism and glaucoma, known hypersensitivity to this class of compounds, agitated states, history of drug abuse, or current or recent use of MAO inhibitors. ADDERALL XR should be prescribed with close physician supervision.

lune 2003

08 Published online by Cambridge University Pres

References: I. Data on file, Shire US Inc., 2003. 2. McCracken JT, Biederman J, Greenhill LL, et al. Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2003;42:673-683. 3. ADDERALL XR package insert. Shire US Inc., 2002. 4. Biederman J, Lopez FA, Boellner SW, Chandler MC. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. *Pediatrics*. 2002;110:258-266. 5. Lopez FA, Ambrosini PJ, Chandler MC, Tulloch SJ, Michaels MA. ADDERALL XR[®] in pediatric ADHD: quality-of-life measures from an open-label community assessment trial. Poster presented at: 14th Annual CHADD International Conference; October 17, 2002; Miami Beach, Fia.

CII Rx Only


BRIEF SUMMARY: Consult the full prescribing information for complete product information.

AMPHETAMINES HAVE A HIGH POTENTIAL FOR ABUSE. ADMINISTRATION OF AMPHETAMINES FOR PROLONGED PERIODS OF TIME MAY LEAD TO DRUG DEPENDENCE. PARTICULAR ATTENTION SHOULD BE PAID TO THE POSSIBILITY OF SUBJECTS OBTAINING AMPHETAMINES FOR NON-THERAPEUTIC USE OR DISTRIBUTION TO OTHERS AND THE DRUGS SHOULD BE PRESCRIBED OR DISPENSED SPARINGLY.

INDICATIONS ADDERALL XR[®] is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The efficacy of ADDERALL XR[®] in the treatment of ADHD was established on the basis of two controlled trials of children aged 6 to 12 who met DSM-IV criteria for ADHD, along with extrapolation from the known efficacy of ADDERALL[®], the immediate-release formulation of this substance. **CONTRAINDICATIONS** Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperhyproldism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma. Agitated states. Patients with a history of drug abuse. During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result). **WARNINGS Psychosis:** Clinical experience suggests that, in psychotic patients, administration of amphetamine may exacerbate symptoms of behavior disturbance and thought disorder. Long-Fern **Suppression of Growth**. Data are inadequate to determine whether chronic use of stimulants in children, including amphetamine, may be causally associated with

suppression of growth. Therefore, growth should be monitored during treatment, and patients who are not growing or gaining weight as expected should have their treatment interrupted. **PRECAUTIONS General:** The least amount of amphetamine feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage. **Hypertension and other Cardiovascular Conditions:** Caution is to be exercised in prescribing amphetamines for patients with even mild hypertension (see CONTRAINDICATIONS). Blood pressure and pulse should be monitored at appropriate intervals in patients taking ADDERALL XR[®], especially patients with hypertension. **Tics:** Amphetamines have been reported to exacerbate motor and phonic tics and Tourette's syndrome. Therefore, clinical evaluation for tics and Tourette's syndrome in children and their families should precede use of stimulant medications. **Information for Patients:**

Amphetamines may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or vehicles; the patient should therefore be cautioned accordingly. Drug Interactions: Acidifying agents-Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCI, ascorbic acid, etc.) lower absorption of amphetamines. Urinary acidifying agents—These agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion. Both groups of agents lower blood levels and efficacy of amphetamines. Advenergic blockers-Advenergic blockers are inhibited by amphetamines. Alkalinizing agents-Gastrointestinal alkalinizing agents (sodium bicarbonate, etc.) increase absorption of amphetamines. Co-administration of ADDERALL XR* and gastrointestinal alkalinizing agents, such as antacids, should be avoided. Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion. Both groups of agents increase blood levels and therefore potentiate the actions of amphetamines Antidepressants, tricyclic-Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents; d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. MAO inhibitors-MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism. This slowing potentiates amphetamines, increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings; this can cause headaches and other signs of hypertensive crisis. A variety of toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results. Antihistamines—Amphetamines may counteract the sedative effect of antihistamines. Antihypertensives-Amphetamines may antagonize the hypotensive effects of antihypertensives. Chlorpromazine—Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning. Ethosuximide-Amphetamines may delay intestinal absorption of ethosuximide. Haloperidol-Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines. Lithium carbonate—The anorectic and stimulatory effects of amphetamines may be inhibited by lithium carbonate. Meperidine-Amphetamines potentiate the analgesic effect of meperidine. Methenamine therapy-Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy. Norepinephrine—Amphetamines enhance the adrenergic effect of norepinephrine. Phenobarbital-Amphetamines may delay intestinal absorption of phenobarbital; co-administration of phenobarbital may produce a synergistic anticonvulsant action. *Phenytoin*—Amphetamines may delay intestinal absorption of phenytoin; co-administration of phenytoin may produce a synergistic anticonvulsant action. *Proposyphene*— In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur. Veratrum alkaloids—Amphetamines inhibit the hypotensive effect of veratrum alkaloids. Drug/Laboratory Test Interactions: Amphetamines can cause a significant elevation in plasma corticosteroid levels. This increase is greatest in the evening. Amphetamines may interfere with urinary steroid determinations. Carcinogenesis/Mutagenesis and Impairment of Fertility: No evidence of carcinogenicity was found in studies in which d,I-amphetamine (enantiomer ratio of 1:1) was administered to mice and rats in the diet for 2 years at doses of up to 30 mg/kg/day in male mice, 19 mg/kg/day in female mice, and 5 mg/kg/day in male and female rats. These doses are approximately 2.4, 1.5, and 0.8 times, respectively, the maximum recommended human dose of 30 mg/day on a mg/m² body surface area basis. Amphetamine, in the enantiomer ratio present in ADDERALL® (immediate-release)(d- to I- ratio of 3:1), was not clastogenic in the mouse bone marrow micronucleus test in vivo and was negative when tested in the E. coli component of the Ames test in vitro. d,I-Amphetamine (1:1 enantiomer ratio) has been reported to produce a positive response in the mouse bone marrow micronucleus test, an equivocal response in the Ames test, and negative responses in the in vitro sister chromatid exchange and chromosomal aberration assays. Amphetamine, in the enantiomer ratio present in ADDERALL* (immediate-release)(d- to I- ratio of 3:1), did not adversely affect fertility or early embryonic development in the rata didese of up to 20 mg/kg/day (approximately 5 lines the maximum recommended human dose of 30 mg/day on a mg/m² body surface area basis). **Pregnancy:** Pregnancy Category C. Amphetamine, in the enantiomer ratio present in ADDERALL[®] (d- to I- ratio of 3:1), had no apparent effects on embryofetal morphological development or survival when orally administered to pregnant rats and rabbits throughout the period of organogenesis at doses of up to 6 and 16 mg/kg/day, respectively. These doses are approximately 1.5 and 8 times, respectively, the maximum recommended human dose of 30 mg/day on a mg/m² body surface area basis. Fetal malformations and death have been reported in mice following parenteral administration of d-amphetamine doses of 50 mg/kg/day (approximately 6 times the maximum recommended human dose of 30 mg/day on a mg/m² basis) or greater to pregnant animals. Administration of these doses was also associated with severe maternal toxicity. A number of studies in rodents indicate that prenatal or early postnatal exposure to amphetamine (d- or d,i-), at doses similar to those used clinically, can result in long-term neurochemical and behavioral alterations. Reported behavioral effects include learning and memory deficits, altered locomotor activity, and changes in sexual function. There are no adequate and well-controlled studies in pregnant women. There has been one report of severe congenital bony deformity, tracheo-esophageal fistula, and anal atresia (vater association) in a baby born to a woman who took dextroamphetamine sulfate with lovastatin during the first trimester of pregnancy. Amphetamines should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nonteratogenic Effects: Infants born to mothers dependent on amphetamines have an increased risk of premature delivery and low birth weight. Also, these infants may experience symptoms of withdrawal as demonstrated by



dysphoria, including agitation, and significant lassitude. **Usage in Nursing Mothers:** Amphetamines are excreted in human milk. Mothers taking amphetamines should be advised to refrain from nursing. **Pediatric Use:** ADDERALL XR[®] is indicated for use in children 6 years of age and older. **Use in Children Under Six** Years of Age: Effects of ADDERALL XR[®] in 3-5 year olds have not been studied. Long-term effects of amphetamines in children have not been well established. Amphetamines are not recommended for use in children under 3 years of age. **Geriatric Use:** ADDERALL XR[®] has not been studied in the geriatric population. **ADVERSE EVENTS** The premarketing development program for ADDERALL XR[®] included exposures in a total of 685 participants in clinical trials (615 patients, 70 healthy adult subjects). These participants received ADDERALL XR[®] at daily doses up to 30 mg. The 615 patients (ages 6 to 12) were evaluated in two controlled clinical study, and one single-dose clinical pharmacology study (N=20). Safety data on all patients are included in the discussion that follows. Adverse reactions were assessed by collecting adverse events, results of physical examinations, vital signs, weights, laboratory analyses, and EGGs. Adverse vents urg exosure were obtained primarily by general inquiry and recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events. The stated frequencies of adverse events represent the proportion of individuals who experienced, at least once, a treatment-temergent adverse event leve is to a use to classify reported adverse events. The stated frequencies of adverse events they is idea.

Adverse events associated with discontinuation of reatament: In two placebo-controlled studies of up to 5 weeks duration, 2.4% (10/425) of ADDERALL XR® treated patients discontinued due to adverse events (including 3 patients with loss of appetite, one of whom also reported insomnia) compared to 2.7% (7/259) receiving placebo. The most frequent adverse events associated with discontinuation of ADDERALL XR® in controlled and uncontrolled, multiple-dose clinical trials (N=595) are presented below. Over half of these patients were exposed to ADDERALL XR® for 12 months or more.

Adverse event	% of patients discontinuing (N=595)
Anorexia (loss of appetite)	2.9
Insomnia	1.5
Weight loss	1.2
Emotional lability	1.0
Depression	0.7

Adverse events occurring in a controlled trial: Adverse events reported in a 3-week clinical trial of pediatric patients treated with ADDERALL XR* or placebo are presented in the table below. The prescriber should be aware that these figures cannot be used to predict the incidence of adverse events in the course of usual medical practice where patient characteristics and other factors differ from those which prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and non-drug factors to the adverse event incidence rate in the population studied.

Table 1 Adverse Events Reported by More Than 1% of Patients Receiving ADDERALL XR® with Highe	r
Incidence Than on Placebo in a 584 Patient Clinical Study	

Body System	Preferred Term	ADDERALL XR®(N=374)	Placebo (N=210)
General	Abdominal Pain (stomachache)	14%	10%
	Accidental Injury	3%	2%
	Asthenia (fatigue)	2%	0%
	Fever	5%	2%
	Infection	4%	2%
	Viral Infection	2%	0%
Digestive System	Loss of Appetite	22%	2%
	Diarrhea	2%	1%
	Dyspepsia	2%	1%
	Nausea	5%	3%
	Vomiting	7%	4%
Nervous System	Dizziness	2%	0%
	Emotional Lability	9%	2%
	Insomnia	17%	2%
	Nervousness	6%	2%
Metabolic/Nutritional	Weight Loss	4%	0%
			1

The following adverse reactions have been associated with amphetamine use: Cardiovascular: Palpitations, tachycardia, elevation of blood pressure. There have been isolated reports of cardiomyopathy associated with chronic amphetamine use. Central Nervous System: Psychotic episodes at recommended doses, overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, exacerbation of motor and phonic tics and Tourette's syndrome. Gastrointestinal: Dryness of the mouth, unpleasant taste, diarrhea, constipation, other gastrointestinal disturbances. Anorexia and weight loss may occur as undesirable effects. Allergic: Urticaria, Endocrine: Impotence, changes in libido, DRUG ABUSE AND DEPENDENCE ADDERALL XR® is a Schedule II controlled substance. Amphetamines have been extensively abused. Tolerance, extreme psychological dependence, and severe social disability have occurred. There are reports of patients who have increased the dosage to many times that recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with amphetamines may include severe dermatoses, marked insomnia, irritability, hyperactivity, and personality changes. The most severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia. OVERDOSAGE Individual patient response to amphetamines varies widely. Toxic symptoms may occur idiosyncratically at low doses. Symptoms: Manifestations of acute overdosage with amphetamines include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states, hyperpyrexia and rhabdomyolysis. Fatigue and depression usually follow the central nervous system stimulation. Cardiovascular effects include arrhythmias, hypertension or hypotension and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Fatal poisoning is usually preceded by convulsions and coma. Treatment: Consult with a Certified Poison Control Center for upto-date guidance and advice. Management of acute amphetamine intoxication is largely symptomatic and includes gastric lavage, administration of activated charcoal, administration of a cathartic and sedation. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendation in this regard. Acidification of the urine increases amphetamine excretion, but is believed to increase risk of acute renal failure if myoglobinuria is present. If acute severe hypertension complicates amphetamine overdosage, administration of intravenous phentolamine has been suggested. However, a gradual drop in blood pressure will usually result when sufficient sedation has been achieved. Chlorpromazine antagonizes the central stimulant effects of amphetamines and can be used to treat amphetamine intoxication. The prolonged release of mixed amphetamine salts from ADDERALL XR* should be considered when treating patients with overdose. Dispense in a tight, light-resistant container as defined in the USP. Store at 25° C (77° F). Excursions permitted to 15-30° C (59-86° F) [see USP Controlled Room Temperature]. Manufactured by DSM Pharmaceuticals Inc., Greenville, North Carolina 27834. Distributed and marketed by Shire US Inc., Newport, KY 41071. For more information call 1-800-828-2088 or visit www.adderallxr.com. ADDERALL® is registered in the US Patent and Trademark Office.

(rev. 10/2002)

403958

CNS SPECTRUMS[®] The International Journal of Neuropsychiatric Medicine

EDITOR

Jack M. Gorman, MD Mount Sinai School of Medicine New York, NY

ASSOCIATE AND FOUNDING EDITOR

Eric Hollander, MD Mount Sinai School of Medicine New York, NY

INTERNATIONAL EDITOR Joseph Zohar, MD Chaim Sheba Medical Center Tel-Hashomer, Israel

ASSOCIATE INTERNATIONAL EDITORS EUROPE Donatella Marazziti MD

Donatella Marazziti, MD University of Pisa Pisa, Italy

MID-ATLANTIC

Dan J. Stein, MD, PhD University of Stellenbosch Tygerberg, South Africa

FAR EAST

Shigeto Yamawaki, MD, PhD Hiroshima University School of Medicine Hiroshima, Japan

CONTRIBUTING WRITERS Gabrielle deVeber, MD Sharon Friefeld, PhD Mehari Gebreyohanns, MD Fenella J. Kirkham, MB BChir F. Andrew Kozel, MS, MD Ruth D. Nass, MD Steven G. Pavlakis, MD Akila Venkataraman, MD

MEDICAL REVIEWER David L. Ginsberg, MD

BOARD OF ADVISORS NEUROLOGISTS

Mitchell F. Brin, MD University of California, Irvine Irvine, CÁ Jeffrey L. Cummings, MD University of California, Los Angeles Los Angeles, CA Jerome Engel, Jr., MD, PhD University of California, Los Angeles Los Angeles, CA Mark S. George, MD Medical University of South Carolina Charleston, SC Deborah Hirtz, MD National Institute of Neurological **Disorders and Stroke, NIH** Rockville, MD Richard B. Lipton, MD Albert Einstein College of Medicine Bronx, NY C. Warren Olanow, MD, FRCPC Mount Sinai School of Medicine New York, NY Steven George Pavlakis, MD Maimonides Medical Center Brooklyn, NY Stephen D. Silberstein, MD, FACP Thomas Jefferson University Philadelphia, PA Michael Trimble, MD, FRCP, FRPsych National Hospital for Neurology and Neurosurgery London, United Kingdom

PSYCHIATRISTS

Margaret Altemus, MD Cornell University Medical College New York, NY Dennis S. Charney, MD National Institute of Mental Health Bethesda, MD Dwight L. Evans, MD University of Pennsylvania Philadelphia, PA Siegfried Kasper, MD University of Vienna Vienna, Austria Martin B. Keller, MD Brown Medical School Providence, RI Lorrin M. Koran, MD Stanford University School of Medicine Stanford, CA Yves Lecrubier, MD Hôpital de la Salpêtrière Paris, France Herbert Y. Meltzer, MD Vanderbilt University Medical Center Nashville, TN Stuart A. Montgomery, MD St. Mary's Hospital Medical School London, United Kingdom Charles B. Nemeroff, MD, PhD Emory University School of Medicine Atlanta, GA Humberto Nicolini, MD, PhD National Mexican Institute of Psychiatry Mexico City, Mexico Stefano Pallanti, MD, PhD University of Florence Florence, Italy Katharine Phillips, MD Brown Medical School Providence, RI Harold A. Pincus, MD Western Psychiatric Institute & Clinic RAND-University of Pittsburgh Health Institute, Pittsburgh, PA Scott L. Rauch, MD Massachusetts General Hospital Charlestown, MA Alan F. Schatzberg, MD Stanford University School of Medicine Stanford, CA Thomas E. Schlaepfer, MD University of Bonn Bonn, Germany Stephen M. Stahl, MD, PhD University of California, San Diego La Jolla, CA Norman Sussman, MD, DFAPA New York University Medical School New York, NY Karen Dineen Wagner, MD, PhD The University of Texas Medical Branch Galveston, Texas Herman G.M. Westenberg, MD University Hospital Utrecht Utrecht, The Netherlands Stuart C. Yudofsky, MD Baylor College of Medicine Houston, TX

 MBL COMMUNICATIONS Corporate Staff

 CEO & PUBLISHER
 A

 Darren L. Brodeur
 B

 ASSOCIATE PUBLISHER
 P

 Elizabeth Katz
 S

 MANAGING EDITOR
 P

 Christopher Naccari
 L

 SENIOR EDITOR
 A

 Deborah Hughes
 L

 Desé R. Ralat
 J

 ACQUISITIONS EDITORS
 N

 Lisa Arrington
 N

ASSISTANT EDITOR Emil J. Ross PUBLISHING ASSOCIATE Shelley Wong PRODUCTION MANAGER Lila Moses ART DIRECTOR Derek Oscarson CONTROLLER John Spano NATIONAL ACCOUNT MANAGER Kelly J. Staley

INFORMATION TECHNOLOGY Clint Bagwell Consulting OFFICE ASSISTANT Manuel Pavón CORPORATION COUNSEL Lawrence Ross, Esq. Bressler, Amery, and Ross

Eileen S. Seligman

Daniel B


ePocrates[®] Clinical Suite of References Found Effective in the Treatment of MIDD

(Medical Information Deficit Disorder)

PRODUCT

We all had senior profe treatment". H can begin only clinical softwa. to heart by cre. extensive drug 1 concise but pow ePocrates Dx). information that ePocrates Rx and for ePocrates Dx program Griffith's not simply bundlec has tightly integra reference work that clinicians who need c see patient on rounds

ePocrates Rx and eP ePocrates Rx is already Clinicians are familiar are organized by both b drug, information is av recommendations), dos contraindications and interactions, retail dru pregnancy data, as well a metabolism. The ePocrati by either brand name (elarithromycin), or by dru



recommend another similar nt's formulary. In addition to ry information, ePocrates Rx crates ID infectious disease cal tables and guidelines, an calculator (adult and peds)

M.D.

Clinical Consult (5MCC) drug monographs within x is organized into over n amyloidosis through Topics are arranged in For each topic, there are s/symptoms", "causes", is", "related topics"," . For example, when I ltiple sclerosis, I was e as well as basic The most powerful recommendations in graphs in ePocrates e sclerosis, I found y, oxybutynin for for acute attacks, sxacerbations. By d their associated nation of dosing.

> d tables with a of medical s for overlan conclude a

Are you suffering from MIDD? Get the integrated drug, formulary and disease information you need at the point of care. Available at www.epocrates.com/cns BRIEF SUMMARY of PRESCRIBING INFORMATION NOICATIONS AND USAGE: Blookar Mania: SEROQUEL is indicated for the short-term treatment of acute manic movements and cardies applied markets. School to molecular to the shortenin resument of school and peoples associated with applied in advorter, as either monotherapy or adjunct therapy to thilm on of valgence. The efficacy of SEROOUEL in acute upplier mania was established in two 3-week monotherapy trials and one 3-week adjunct therapy trial of bupoler jacteris sinkally hospitalized for up to 7 days for acute mana. Effectiveness for adjunct therapy their di bopier i patients inhally insoptiated for up to 7 days for acute mains. Elterkivensis tru more than a week stano been systemically evaluated in clinical trusts. Therefore, the physician who elevates to use SRROUELs to extended periods should periodically revaluate the iong-term risks and benefits of the drug to the individual patier. The Skabophaniers: SSROUELLs in indicated for the terament of scharophrenia. The efficiency of SRROUELs in scharophrenia avail sessibility of the terament of scharophrenia. The efficiency of SRROUELs in scharophrenia available in short-term (6-week) controlled trusts of scharophrenia in patients available in controlled trusts. Therefore, the physician who elects to use SRROUEL for excluded periods should periodically evaluate the fong-term use trust is, in the in clinical period. For excluded periods should periodically evaluate the fong-term use trust is, in the individual period. For excluded periods should periodically evaluate the fong-term use trust is, the individual period. Should period should periodically evaluate the fong-term use trust is, the individual period. Should period should periodically evaluated in the fong-term use trust is, the individual period. Should period should periodically evaluated in the fong-term use trust is, the individual period. Should period should periodically evaluated in the fong-term use trust is, the individual period. Should period should period and the schule the fong-term use trust is, the individual period. The schule the individual period. The individual period should period should period. The schule the individual period. The schule the fong-term use trust is, the individual period. The schule the indident period. The schule the individual period. The schule the

CONTRAINDICATIONS: SEROOUEL is contraindicated in individuals with a known hypersensitivity to this medica

periodically re-induce the long-term settliness of the drug for the individual patient. **CORTINUMCLATIONS:** SEPOLIEL is contraindicated in individuals with a known hypersensitivity to this medica-tion at any of its opposition. **WARROS:** Neurolepid Malignant Syndrome (MKS): A potentially taid symptom complex sometimes referred to a knowclebic Malignant Syndrome (MKS): has been enropid and a manifestation of antipsychic drugs, mucking SEPOLIEL. Bure cases of MKS have been recorded with SEPOLUEL initial manifestations and the syndrome. Individual Sector Malignant Syndrome (MKS): A potentially taid symptom complex sometimes referred to the syndrome. Individual Sector Malignant Syndrome (MKS): A potentially taid a manifestation of a patients with the syndrome is complicated. In anning a diagnosis, it is important to exclude cases where the clinical pre-sentation includes the syndrome is complicated. In anning a diagnosis, it is important considerations in the differential data patient includes the syndrome is complicated. In anning a diagnosis, it is important considerations in the differential data patient includes to consument theory. J intensive syndromic transmittent data medical monotining: a data in the syndrome is complicated. In anning a diagnosis, it is important considerations in the differential data patient single base is the syndrome is present in the syndrome is transmittent and the diagnosis in the differential data. There is a syndrome is the single syndrome is the single syndrome is the single syndrome is monoting and the sector register and there is a syndrome is a syndrome is the single syndrome in the differential data in the differential data in the differential data is the syndrome in the syndrome is indiverse in the syndrome is the syndrome is the syndrome is the syndrome is a syndrome is a syndrome is a syndrome in the syndrome is the syndrome in the syndrome is syndrome in the differential data is a syndrome in th

operand euroge reatment was appead antosychotics should undergo tasting paloo glucces testing, in some cases, propertycem is a resolved when the sprand antosychotic was discontinued; howevers, some paleties required continuation of anti-diabetic treatment despite discontinuation of the suspect drug. PRECARTIONES Centeral: Onboatetic Representation of the suspect of the patients treated with SEROOLEL. compared with 0% (GMO2) on placeto and palou 0.4% (25227) on active control drugs conditions which would orediscopes allies to hypotensics and survices with anti-hypertreative medications. The nick of orthostatic hypotension and survices must be minimized by limiting the in-tration schedule is appropriate. Calaracts: The development of cataracts was abserved in association with survice has not been established. Heverentials, the normaline of previous does in the tration schedule is appropriate Calaracts: The development of cataract was abserved in association with survice has not been established. Heverentials, such assist and anti-hypertreative and the sub-state bean baserve in patients under generations and survices and no 2% (CS77) on active control orugs. As with other antipochoics SEROOUEL treatment, but a causal nationability 05% on active control orugs. As with other antipochoics SEROOUEL treatment of 14 (addros) and no 17% (CS77) on advice control orugs. As with other antipochoics SEROOUEL stratic basers and no 2% (CS77) on active control orugs. As with other antipochoics SEROOUEL stration ato the tother respectively, compared to stypic decreases for placebo patients. These changes were only weakly related to the increases in weight decreased is REOOUEL- related patients. Rhopportaletimisms, Althoogh an elevation of pro-lactin levels was not demonstrated in clinical trats with SEROOUEL increased protach levels were observed in rat-studies with his compound, and were associated with an increase in manning y data requested in rads (see Carningenersis). Tassie culture experiments indicate that approximately one-third of human hirsest cancers are pro-maria, and implement with or a chord or determination of the mercoription of these drugs is controlled in a patient with previously detected breast cancer. Although disturbances such as galactorima, amenorma, gono maria, and implement have been reported with producin-textoring compounds. It was a distance and weath reports of the endous is constrained and serum protach in werds is unknown for most patients. Neither clinical studies on epidemiologic studies conducted serum protach in werds is unknown for most patients. Neither clinical studies on a distance of the endous serum protach in werds is considered too limited to be concluse at this time. Transaminasse (endous) serum are response and on a 200 d 3 to favore dual classes the apport limits of the schoorbernia traits, the proportions of patients with transaminasse elevations of 3 s times the available wedness is considered too limited to be concluse at this set of apportionally of Six to SEROUEL compared to 1% for placebo in scale biopiar main traits, the proportions of patients with transaminase elevations of 3 times the outper limits of the moreingly returned to the school patients with attransaminase elevations of 3 times the outper limits with a moreingly returned to the Six Questo Controlled traits were apportantely 1% for both SEROUEL compared to 1% of placebo galants. In acute biopiar main traits using statement and control by series of that discrete series reported in the school preturned traits wereing

SERODUEL® (quetiapine furmarate) Tablets

SectorUse: (updation to instance of the sector of the sect Settoructur- (querespine tumaritate) fabries
So to 124% Excepto Control Gindina (Tails for the Testment of Schizophrenia and Acate Bjodar Mania (montherap)). Bogs as Whole Headback Pain, Asternia Pain, Back Pain, Feer, Carllinssatalitz Carlyna, Transperioda Incrussed, Meriade Land Methinaet, Hoyal Land, SCH Increased, SCH Lincssed, Meriade Landon, Carloss, Marine Jano, Back Pain, Feer, Carllinssatalitz Carlyna, Transperioda Increased, Meriade Landon, Carloss, Marine Jano, Sunta, Marine Jano, Cong, Tarrased, Jongson, Garthae, editoryania Syndhom, Tolinski, Mohara Ban, Jong Karlyna, Tonnes, Marine Sale, and Karlyna, K

observed todecy for signs or mesule of aduse to berk/UDEL, e.g., bevecprimen or lowarable, increases in doas, doing seeking balancie. OVERD025AGE: Human experience: Experience with SEROQUEL, (quetapine tumarate) in acute overdosage was limited in the clinical trait database (6 reports) with estimated does ranging from 1200 mg b630 mg and no faalities. In general, reported signs and symptoms were those resulting from an exagesation of the drugs an estimated overdose of 9600 mg, was associated with hypolatienia and first depres heart allock. In post-heart acute an estimated overdose of 9600 mg, was associated with hypolatenia and first depres heart allock. In post-mice acute and ensure adequet acygeration and verification (acute acute acute) acute acut induced alpha blockade). In cases of severe extrapyramidal symptoms, anticholinergic medication should be administered. Close medical supervision and monitoring should continue until the patient recovers. SEROQUEL is a trademark of the AstraZeneca group of companies.

SEROQUEL® (quetiapine fumarate) Tablets

surversi commons: synotome (SSS) DRUG ABUSE AND DEPENDENCE Characterial database Class: SERIOUEL is not a controlled substance. Physical and Psychologi dependence: SERIOUEL has not been systemiatually slubided, in animats on humans, hor is polen-tial for abuse, lowrance or physical dependence. While the chinal hairs dation trevel any tendency for any drop-solarity behavior, these observations were to systematic and its to possible to perform the loss to the limit el expension; the estemit to which a OKS-active drop will be misseed, directed, and/or double donote mailstance and development the estemit to which a OKS-active drop will be misseed. (Hereby, and/or double donote indicative development the estemit to which a OKS-active drop will be misseed. (Hereby, and/or double donote indicative development the estemit to which a OKS-active drop will be misseed. (Hereby, and/or double donote indicative development the estemit to which a OKS-active drop will be misseed. (Hereby, and/or double double to be the development the estemit to which a OKS-active drop will be misseed.) (Hereby, and/or double double to be able development the estemit to which a OKS-active drop will be misseed.) (Hereby, and/or double double to be the development the estemit to which a OKS-active drop will be misseed.) (Hereby, and/or double double to be the development of interactive a double of SERIOUEL, e.g., development of interactive, increases in doeg, (Hereby, and/or double doubl

Manufactured for: AstraZeneca Pharmaceuticals LP Wilmington, Delaware 19850-5437

NOW FDA approved for MANIA IN BIPOLAR DISORDER

Another great reason to prescribe

1/71

Effective so patients improve^{1,3}

 Trusted tolerability so patients can stay on treatment^{1,4,5}

The safety and efficacy of SEROQUEL in pediatric patients have not been established.

Patients should be periodically reassessed to determine the need for continued treatment.

Prescribing should be consistent with the need to minimize the risk of tardive dyskinesia, seizures, and orthostatic hypotension. A rare condition referred to as neuroleptic malignant syndrome (NMS) has been reported with this class of medications, including SEROQUEL.

There have been reports of diabetes mellitus and hyperglycemia-related adverse events associated with the use of atypical antipsychotics, including SEROQUEL.

The most common adverse events associated with the use of SEROQUEL were somnolence, dry mouth, dizziness, constigation, asthenia, abdominal pain, postural hypotension, pharyngitis, SGPT increase, dyspepsia, and weight gain.

In bipolar mania trials, withdrawal rates due to adverse events were similar to placebo for SEROQUEL as monotherapy (SEROQUEL 5.7%, placebo 5.1%) and adjunct therapy (SEROQUEL plus lithium or divalproex 3.6%, lithium or divalproex alone 5.9%).

References: 1. SEROQUEL® (quetiapine fumarate) Prescribing Information, Rev 01/04, AstraZeneca Pharmaceuticals LP, Wilmington, Delaware. 2. Data on file, DA-SER-13, AstraZeneca Pharmaceuticals LP, Wilmington, Delaware. 3. Data on file, DA-SER-15, AstraZeneca Pharmaceuticals LP, Wilmington, Delaware. 4. Data on file, DA-SER-14, AstraZeneca Pharmaceuticals LP, Wilmington, Delaware. 5. Data on file, DA-SER-16, AstraZeneca Pharmaceuticals LP, Wilmington, Delaware.



To prevent medication errors, write "*SEROQUEL*" clearly on your Rx pad. Spell "*SEROQUEL*" clearly over the phone. Please see Brief Summary of Prescribing Information on following page.



First-line treatment

AstraZeneca Pharmaceuticals LP

www.SEROQUEL.com



Table of Contents

- **418 Introduction: Little Folk Strokes: Current Questions** Steven G. Pavlakis, MD, *Maimonides Medical Center*; and Gabrielle deVeber, MD, *University of Toronto*
- **420** Recovery After Acquired Stroke in Childhood Ruth D. Nass, MD, New York University Medical Center; and Doris Trauner, MD, University of California, San Diego School of Medicine
- **436** Newborn Brain Infarction: Clinical Aspects and Magnetic Resonance Imaging Akila Venkataraman, MD, Maimonides Medical Center; Peter B. Kingsley, PhD, North Shore University Hospital; Peter Kalina, MD, Mayo Clinic; Steven G. Pavlakis, MD, Maimonides Medical Center; Sharon Buckwald, MD, North Shore University Hospital; Regina Spinazzola, MD, North Shore University Hospital; and Rita Harper, MD, North Shore University Hospital
- **445** Sickle Cell Disease: Primary Stroke Prevention Mehari Gebreyohanns, MD, Medical College of Georgia; and Robert J. Adams, MS, MD, Medical College of Georgia
- **451** Risk Factors for Arterial Ischemic Stroke in Childhood Fenella J. Kirkham, MB BChir, Southampton General Hospital; and Alexandra M. Hogan, PhD, University of Southampton
- **465** Health-Related Quality of Life and Its Relationship to Neurological Outcome in Child Survivors of Stroke Sharon Friefeld, PhD, University of Toronto; Ophelia Yeboah, BSc, University of Toronto; Janalynn E. Jones, BSc, University of Toronto; and Gabrielle deVeber, MD, University of Toronto
- 476 Decision Analysis of Cost-Effectiveness of Repetitive Transcranial Magnetic Stimulation Versus Electroconvulsive Therapy for Treatment of Nonpsychotic Severe Depression F. Andrew Kozel, MS, MD, Medical University of South Carolina; Mark S. George, MD, Medical University of South Carolina; and Kit N. Simpson, Dr PH, Medical University of South Carolina

EDITORIAL MISSION

CNS Spectrums' editorial mission is to address relevant neuropsychiatric topics, including the prevalence of comorbid diseases among patients, and original research and reports that emphasize the profound diagnostic and physiologic connections made within the neurologic and psychiatric fields. The journal's goal is to serve as a resource to psychiatrists and neurologists seeking to understand and treat disturbances of cognition, emotion, and behavior as a direct consequence of central nervous system disease, illness, or trauma.



Table of Contents

Departments/Monthly Columns

FROM THE EDITOR'S DESK

412 Stroke Where You Least Expect It By Jack M. Gorman, MD

CLINICAL UPDATES IN NEUROPSYCHIATRY

- **413** News From the 157th Annual Meeting of the American Psychiatric Association
 - Researchers Review Relationships Between Sleep Disturbances, Major Depressive Disorder, and Alcohol Intake
 - Study Finds Standard-of-Care For Treatment-Refractory Depression Patients Inadequate
 - Remission Determined Via Clinically Useful Depression Outcome Scale
- **415** News From the 56th Annual Meeting of the American Academy of Neurology
 - Psychiatric Side Effects and Antiepileptic Drugs: What Are the Identifying Markers?
 - Atypical Forms of Depression Common in Epilepsy
 - Short Version of Severe Impairment Battery Indicates Promise as Severe Dementia Measure

CONTINUING MEDICAL EDUCATION

- **484** Pediatric and Newborn Stroke CME-accredited by Mount Sinai School of Medicine for 3.0 credit hours.
- 486 July Pretest: Genetics in Eating Disorders

Founded in 1996, *CNS Spectrums* is an *Index Medicus* journal and is available on MEDLINE under the citation *CNS Spectr.* It is available online at www.cnsspectrums.com.

CNS Spectrums (ISSN 1092-8529) is published monthly by MBL Communications, Inc. 333 Hudson Street, 7th Floor, New York, NY 10013.

One-year subscription rates: domestic \$120; foreign \$185; in-training \$75. For subscriptions: Phone: 212-328-0800; Fax: 212-328-0600; Web: www.cnsspectrums.com.

Postmaster: Send address changes to *CNS Spectrums* c/o PPS Medical Marketing Group 264 Passaic Avenue, Fairfield, NJ 07004-2595.

For editorial inquiries, please fax us at 212-328-0600 or e-mail us at jrr@mblcommunications.com. For bulk reprint purchases, please contact: Kelly J. Staley at kjs@mblcommunications.com.

Opinions and views expressed by authors are their own and do not necessarily reflect the views of the publisher, MBL Communications, Inc., or the editorial advisory board. Advertisements in *CNS Spectrums* are accepted on the basis of adherence to ethical medical standards, but acceptance does not imply endorsement by *CNS Spectrums* or the publisher.

CNS Spectrums is a registered trademark of CNS Spectrums, LLC, New York, NY. Permission to reproduce articles in whole or part must be obtained in writing from the publisher. Audit Bureau of Circulations member.

Copyright ©2004 by MBL Communications, Inc. All rights reserved. Printed in the United States.

CNS SPECTRUMS ONLINE

This month's issue of CNS Spectrums, as well as a host of educational resources, enduring materials, and archived issues, is available at www.cnsspectrums.com.

Volume 9 – Number 6

GO BEYOND THE MAX

Introducing **NEW 25** mg and 50 mg capsules of ZONEGRAN® (zonisamide)



ZONEGRAN is indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy.

In clinical trials, the most common adverse events that occurred with ZONEGRAN were somnolence, dizziness, anorexia, headache, nausea, and agitation/irritability.

*Can also be dosed twice daily.

Please see brief summary of Prescribing Information on adjacent page.

References: 1. ZONEGRAN® Prescribing Information. Elan Pharmaceuticals. 2002. 2. Brodie M, Wilson E, Smith D, et al. Steady-state drug interaction study of zonisamide and lamotrigine in epileptic patients. *Neurology*. 2001;56(3):A337 (abstract). 3. Data on file. Elan Pharmaceuticals, Inc.

élan

Distributed by Elan Biopharmaceuticals, a business unit of Elan Pharmaceuticals, Inc. (EPI), a member of the Elan Group, ZONEGRAN and the **72**, are trademarks of, or licensed exclusively in the U.S. to, EPI. ©2003 Elan Pharmaceuticals, Inc. Printed in USA ZNS-12120903 www.elan.com

More dosing options for meeting patients' needs

- Increase your dosing flexibility
- Choose from 3 dosage strengths:
 25 mg, 50 mg, and 100 mg capsules
- Tailor therapy to the individual patient

Proven efficacy with confidence-building benefits¹⁻³

- Few drug-to-drug interactions
- Minimal cognitive impairment
- 63-hour half-life—the longest of any newer AED
- Convenient QD dosing^{*}



CONTRAINDICATIONS

ZONEGRAN is contraindicated in patients who have demonstrated hypersensitivity to sulfonamides or zonisamide.

Potentially Fatal Reactions to Sulfonamides: Fatalities have occurred, although rarely, as a result of severe reactions to sulfonamides (zonisamide is a sulfonamide) including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Such reactions may occur when a sulfonamide is readministered irrespective of the route of administration. If signs of hypersensitivity or other serious reactions occur, discontinue zonisamide immediately. Specific experience with sulfonamide-type adverse reaction to zonisamide is described below.

below. Serious Skin Reactions: Consideration should be given to discontinuing ZONEGRAN in patients who develop an otherwise unexplained rash. If the drug is not discontinued, patients should be observed frequently. Seven deaths from severe rash (i.e. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN]) were reported in the first 11 years of marketing in Japan. All of the patients were receiving other drugs in addition to zonisamide. In postmarketing experience from Japan, a total of 49 cases of SJS or TEN have been reported, a reporting rate of 46 per million patient-years of exposure. Although this rate is greater than background, it is probably an underestimate of the true incidence because of under-reporting. There were no confirmed cases of SJS or TEN in the US, European, or Japanese development programs.

In the US and European randomized controlled trials, 6 of 269 (2.2%) zonisamide patientsdiscontinued treatment because of rash compared to none on placebo. Across all trials during the US and European development, rash that led to discontinuation of zonisamide was reported in 1.4% of patients (12.0) events per 1000 patient-years of exposure). During Japanese development, serious rash or rash that led to study drug discontinuation was reported in 2.0% of patients (27.8 events per 1000 patient years). Rash usually occurred early in treatment, with 85% reported within 16 weeks in the US and European studies and 90% reported within two weeks in the Japanese studies. There was no apparent relationship of dose to the occurrence of rash.

Serious Hematologic Events: Two confirmed cases of aplastic anemia and one confirmed case of agranulocytosis were reported in the first 11 years of marketing in Japan, rotes greater than generally accepted background rotes. There were no cases of aplastic anemia and two confirmed cases of agranulocytosis in the US, European, or Japanese development programs. There is inadequate information to assess the relationship, if any, between dose and duration of treatment and these events.

Oligohidrosis and Hyperthermia in Pediatric Patients:

Oligohidrosis, sometimes resulting in heat stroke and hospitalization, is seen in association with zonisamide in pediatric patients.

During the pre-approval development program in Japan, one case of oligohidrosis was reported in 403 pediatric patients, on incidence of 1 case per 285 patient-years of exposure. While there were no cases reported in the US or European development programs, fewer than 100 pediatric patients participated in these trials.

In the first 11 years of marketing in Japan, 38 cases were reported, an estimated reporting rate of about 1 case per 10,000 patient-years of exposure. In the first year of market ing in the US, 2 cases were reported, an estimated reporting rate of about 12 cases per 10,000 patient-years of exposure. These rates are underestimates of the true incidence because of under reporting. There has also been one report of heat stroke in an 18-year-old patient in the US.

Decreased sweating and an elevation in body temperature above normal characterized these cases. Many cases were reported after exposure to elevated environmental temperatures. Heat stroke, requiring hospitalization, was diagnosed in some cases. There have been no reported deaths.

cases. Intere have been no reported deaths. Pediatric patients appear to be at an increased risk for zonisamide-associated oligohidrosis and hyperthermia. Patients, especially pediatric patients, treated with Zonegran should be monitored closely for evidence of decreased sweating and increased body temperature, especially in warm or hot weather. Caution should be used when zonisamide is prescribed with other drugs that predispose patients to heatrelated disorders; these drugs include, but are not limited to, carbonic anhydrase inhibitors and drugs with anticholinergic activity.

The practitioner should be aware that the safety and effectiveness of zonisamide in pediatric patients have not been established, and that zonisamide is not approved for use in pediatric patients.

Seizures on Withdrawal: As with other AEDs, abrupt withdrawal of ZONEGRAN in patients with epilepsy may precipitate increased seizure frequency or status epilepticus. Dose reduction or discontinuation of zonisamide should be done gradually.

or discontinuation of zonisamide should be done gradually. **Teratogenicity:** Women of child bearing potential who are given zonisamide should be advised to use effective contraception. Zonisamide was teratogenic in mice, rats, and dogs and embryolethal in mankeys when administered during the period of organogenesis. A variety of fetal abnormalities, including cardiovascular defects, and embryo-fetal deaths occurred at maternal plasma levels similar to or lower than therapeutic levels in humans. These findings suggest that the use of ZONE-GRAN during pregnancy in humans may present a significant risk to the fetus (see **PRECAUTIONS, Pregnancy** subsection). It cannot be said with any confidence, however, that even mild seizures do not pose some hazards to the developing fetus. Zonisamide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus: Use of ZONEto continvey. Neuropsychiatric Adverse Events: Use of ZONE-

Cognitive/ Neuropsychiatric Adverse Events: Use of ZONE-GRAN was frequently associated with central nervous systemrelated adverse events. The most significant of these can be classified into three general categories: 1) psychiatric symptoms, including depression and psychosis, 2) psychomotor slowing, difficulty with concentration, and speech or language problems, in particular, word-finding difficulties, and 3) somnolence or tatigue.

In placebo-controlled trials, 2.2% of patients discontinued ZONEGRAN or were hospitalized for depression compared to 0.4% of placebo patients, while 1.1% of ZONEGRAN and 0.4% of placebo patients, while 1.1% of ZONEGRAN and and 1.0% were hospitalized because of reported depression or suicide attempts. In placebo-controlled trials, 2.2% of patients discontinued ZONEGRAN or were hospitalized due to psychosis or psychosis-related sequence to none of the placebo patients. Among all epilepsy patients treated with ZONEGRAN, 0.9% were discontinued and 1.4% were hospitalized talized because of reported psychosis or related symptoms.

Psychomotors of reported and difficulty with concentration occurred in the first month of treatment and were associated with doses above 300 mg/day. Speech and language problems tended to occur after 6–10 weeks of treatment and at doses above 300 mg/day. Although in most cases these events were of mild to moderate severity, they at times led to withdrawal from treatment.

Somnolence and fatigue were frequently reported CNS adverse events during clinical trials with ZONEGRAN. Although in most cases these events were of mild to moderate severity, they led to withdrawal from treatment in 0.2% of the patients enrolled in controlled trials. Somnolence and fatigue tended to occur within the first month of treatment. Somnolence and fatigue occurred most frequently at doses of 300–500 mg/day. Patients should be taken by patients if they drive, operate machinery, or perform any hazardous task.

PRECAUTIONS

General: Somolence is commonly reported, especially at higher doses of ZONEGRAN (see **WARNINGS: Cognitive/ Neuropsychiatric Adverse Events** subsection). Zonisamide is metabolized by the liver and eliminated by the kidneys; caution should therefore be exercised when administering ZONEGRAN to patients with hepatic and renal dysfunction (see **CLINICAL PHARMACOLOGY**, **Special Populations** subsection of full Precribing Information).

Isee CLINCAL PRAKINGCIGOF, Special ropulations subsection of full Precribing Information). Kidney Stones: Among 991 patients treated during the development of ZONEGRAN, 40 patients (4.0%) with epilepsy receiving ZONEGRAN developed clinically possible or confirmed kidney stones (e.g. clinical symptomatology, sonography, etc.), a rate of 34 per 1000 patient-years of exposure (40 patients with 1168 years of exposure). Of these, 12 were symptomatic, and 28 were described as possible kidney stones based on sonographic detection. In nine patients, the diagnosis was confirmed by a passage of a stone or by a definitive sonographic finding. The rate of occurrence of kidney stones was 28.7 per 1000 patient-years of exposure in the first six months, 62.6 per 1000 patient-years of exposure between 6 and 12 months, and 24.3 per 1000 patient-years of exposure after 12 months, one 3.7 per 1000 patient-years of exposure infer 12 months or use. There are no normative sonographic data available for either the general population or patients with epilepsy. The clinical significance of the sonographic finding is unknown. The analyzed stones were composed of calcium or urate salts. In general, increasing fluid intake and urine output those with predisposing risk factors. It is unknown, however, whether these measures will reduce the risk of stone formation in patients treated with ZONEGRAN.

in patients treated with ZONEGRAN. Effect on Renal Function: In several clinical studies, zonisamide was associated with a statistically significant 8% mean increase from baseline of serum creatinine and blood urea nitrogen (BUN) compared to essentially no change in the placebo patients. The increase appeared to persist over time but was not progressive; this has been interpreted as an effect on glomerular filtration rate (GFR). There were no episodes of unexplained acute renal failure in clinical development in the US, Europe, or Japan. The decrease in GFR appeared within the tirst 4 weeks of treatment. In a 30-day study, the GFR returned to baseline within 2–3 weeks of drug discontinuation. There is on information about reversibility, after drug discontinuation, for the effects on GFR other long-term use. ZONEGRAN should be discontinued in patients who develop acute renal failure or clinically significant sustained increase in the creatinine/BUN concentration. ZONEGRAN should not be used in patients with renal failure (estimated GFR < 50 mL/min) as there has been insufficient experience concerning drug dosing and toxicity.

insufficient experience concerning drug dosing and toxicity. Sudden Unexplained Death in Epilepsy: During the development of ZONEGRAN, nine sudden unexplained deaths occurred among 991 patients with epilepsy receiving ZONE-GRAN for whom accurate exposure data are available. This represents an incidence of 7.7 deaths per 1000 patient years. Although this rate exceeds that expected in a healthy population, it is within the range of estimates for the incidence of sudden unexplained deaths in patients with refractory epilepsy not receiving ZONEGRAN (ranging from 0.5 per 1000 patient-years for the general population of patients with refractory epilepsy, to 2–5 per 1000 patient-years for patients with refractory epilepsy; higher incidences range from 9–15 per 1000 patient years among surgical candidates and surgical failures). Some of the deaths could represent seizure-related deaths in which the seizure was not observed. Status Eoilepticus: Estimates of the incidence of treatment

Status Epilepticus: Estimates of the incidence of treatment emergent status epilepticus in ZONEGRAN-treated patients are difficult because a standard definition was not employed. Nonetheless, in controlled trials, 1.1% of patients treated with ZONEGRAN had an event labeled as status epilepticus compared to none of the patients treated with placebo. Among patients treated with ZONEGRAN across all epilepsy studies (controlled and uncontrolled), 1.0% of patients had an event reported as status epilepticus.

Creatine Phosphokinase (CPK) Elevation and Pancreatitis: In the post-market setting, the following rare adverse events have been observed (<1:1000):

If patients taking zonisamide develop severe muscle pain

https://doi.org/10.1017/S109285290000+9408 Published online by Cambridge University Press

and/or weakness, either in the presence or absence of a fever, markers of muscle damage should be assessed, including serum CPK and aldolase levels. If elevated, in the absence of another obvious cause such as trauma, grand mal seizures, etc., tapering and/or discontinuance of zonisamide should be considered and appropriate treatment initiated.

Patients taking zonisamide that manifest clinical signs and symptoms of pancreatitis should have pancreatic lipose and anylase levels monitored. If pancreatitis is evident, in the absence of another obvious cause, tapering and/or discontinuation of zonisamide should be considered and appropriate treatment initiated.

Information for Patients: Patients should be advised as follows:

- ZONEGRAN may produce drowsiness, especially at higher doses. Patients should be advised not to drive a car or operate other complex machinery until they have gained experience on ZONEGRAN sufficient to determine whether it affects their performance.
- Patients should contact their physician immediately if a skin rash develops or seizures worsen.
- 3. Patients should contact their physician immediately if they develop signs or symptoms, such as sudden back pain, abdominal pain, and/or blood in the urine, that could indicate a kidney stone. Increasing fluid intake and urine output may reduce the risk of stone formation, particularly in those with predisposing risk factors for stones.
- Patients should contact their physician immediately if a child has been taking ZONEGRAN and is not sweating as usual with or without a fever.
- Because zonisamide can cause hematological complications, patients should contact their physician immediately if they develop a fever, sore throat, and ulcers, or easy bruising.
- 6. As with other AEDs, patients should contact their physician if they intend to become pregnant or are pregnant during ZONEGRAN therapy. Patients should notify their physician if they intend to breast-feed or are breast-feeding an infant.
- Patients should contact their physician immediately if they develop severe muscle pain and/or weakness.

Laboratory Tests: In several clinical studies, zonisamide was associated with a mean increase in the concentration of serum creatinine and blood uree nitrogen (BUN) of approximately 8% over the baseline measurement. Consideration should be given to monitoring renal function periodically (see PRECAU-TONS, Effect on Renal Function subsection).

Zonisamide was associated with an increase in serum alkaline phosphatase. In the randomized, controlled trials, a mean increase of approximately 7% over baseline was associated with zonisamide compared to a 3% mean increase in placebo-treated patients. These changes were not statistically significant. The clinical relevance of these changes is unknown.

The clinical relevance of these changes is unknown. **Drug Interactions:** Effects of ZONEGRAN on the pharmacokinetics of other antiepilepsy drugs (AEDs): Zonisamide had no appreciable effect on the steady state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials. Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro. Zonisamide is not expected to interfere with the metabolism of other drugs that are metabolized by cytochrome P450 isozymes.

Itzed by cytochrome FADD isozymes. Effects of other drugs on ZONEGRAN pharmacokinetics: Drugs that induce liver enzymes increase the metabolism and clearance of zonisamide and decrease its half-life. The half-life of zonisamide following a 400 mg dose in patients concurrently on enzyme-inducing AEDs such as phenytoin, corbamazepine, or phenobarbital was between 27–38 hours; the half-life of zonisamide in patients concurrently on the non-enzyme inducing AED, valproate, was 46 hours. Concurrent medication with drugs that either induce or inhibit CYP3A4 would be expected to aller serum concentrations of zonisamide.

Interaction with cimetidine: Zonisamide single dose pharmacokinetic parameters were not affected by cimetidine (300 mg four times a day for 12 days).

Carcinogenicity, Mutagenesis, Impairment of Fertility: No evidence of carcinogenicity was found in mice or rats following dietary administration of zonisamide for two years at doses of up to 80 mg/kg/day. In mice, this dose is approximately equivalent to the maximum recommended human dose (MRHD) of 400 mg/day on a mg/m² basis. In rats, this dose is 1–2 times the MRHD on a mg/m² basis.

Zonisamide increased mutation frequency in Chinese hamster lung cells in the absence of metabolic activation. Zonisamide was not mutagenic or clastogenic in the Ames test, mouse lymphoma assay, sister chromatid exchange test, and human lymphocyte cytogenetics assay *in vitro*, and the rat bane marrow cytogenetics assay *in vitro*.

Rats treated with zonisamide (20, 60, or 200 mg/kg) before mating and during the initial gestation phase showed signs of reproductive toxicity (decreased corpora lutea, implantations, and live fetuses) at all doses. The low dose in this study is approximately 0.5 times the maximum recommended human dose (MRHD) on a mg/m² basis. The effect of zonisamide on human fertility is unknown.

Pregnancy: Pregnancy Category C (see WARNINGS, Teratogenicity subsection): Zonisamide was teratogenic in mice, rats, and dogs and embryolethal in monkeys when administered during the period of organogenesis. Fetal abnormalities or embryo-fetal deaths occurred in these species at zonisamide dosage and maternal plasma levels similar to ar lower than therapeutic levels in humans, indicating that use of this drug in pregnancy entails a significant risk to the fetus. A variety of external, visceral, and skeletal malformations was produced in animals by prenatal exposure to zonisamide. Cardiovascular defects were prominent in both rats and dogs.

Following administration of zonisamide (10, 30, or 60 mg/kg/day) to pregnant dogs during organogenesis, increased incidences of fetal cardiovascular malformations (ventricular

septal defects, cardiomegaly, various valvular and arterial anomalies) were found at doses of 30 mg/kg/day or greater. The low effect dose for malformations produced peak mater-nal plasma zonisamide levels (25 µg/ml) about 0.5 times the highest plasma levels measured in patients receiving the maximum recommended human dose (MRHD) of 400 mg/day. In dogs, cardiovascular malformations were found in approximately 50% of all fetuses exposed to the high dose, which was associated with maternal plasma levels (44 µg/ml) approximately equal to the highest levels measured in humans receiving the MRHD. Incidences of skeletal malformations were also increased frequencies of skeletal variations were seen at all doses in this study. The low dose produced maternal plasma levels (12 µg/ml) about 0.25 times the highest human levels. In comondaus monkeys, administration of zonisamide (10 or

reverse (12 pg/mg about 0.22 times the highest human levels. In cynomolgus monkeys, administration of zonisamide (10 or 20 mg/kg/day) to pregnant animals during organogenesis resulted in embryo-fetal deaths at both doses. The possibility that these deaths were due to malformations cannot be ruled out. The lowest embryolethal dose in monkeys was associated with peak maternal plasma zonisamide levels (5 µg/ml) ap-proximately 0.1 times the highest levels measured in patients at the MRHD.

at the MKHD. In a mouse embryo-fetal development study, treatment of preg-nant animals with zonisamide [125, 250, or 500 mg/kg/day] during the period of organogenesis resulted in increased incidences of fetal malformations (skeletal and/or craniofacial defects) at all doses tested. The low dose in this study is ap-proximately 1.5 times the MRHD on a mg/m² basis. In rats, in-creased frequencies of malformations (cardiovascular defects) and variations (persistent cards of thymic tissue, decreased skeletal ossification) were observed among the offspring of dams treated with zonisamide [20, 60, or 200 mg/kg/day] throughout organogenesis at all doses. The low effect dose is approximately 0.5 times the MRHD on a mg/m² basis.

Perinatal death was increased among the offspring of rats treated with zonisamide (10, 30, or 60 mg/kg/day) from the latter part of gestation up to weaning at the high dose, or approximately 1.4 times the MRHD on a mg/m² basis. The no effect level of 30 mg/kg/day is approximately 0.7 times the MRHD on a mg/m² basis.

There are no adequate and well-controlled studies in pregnant women. ZONEGRAN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Labor and Delivery: The effect of ZONEGRAN on labor and delivery in humans is not known.

Delivery in numans is not known. Use in Nursing Mothers: It is not known whether zonisamide is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infonts from zonisamide, a decision should be made whether to discontinue nursing or to discontinue drug, taking into account the importance of the drug to the mother. ZONEGRAN should be used in nursing mothers only if the benefits outweigh the risks.

Pediatric Use: The sofety and effectiveness of ZONEGRAN in children under age 16 have not been established. Cases of oligohidrosis and hyperpyrexia have been reported (see WARNINGS, Oligohidrosis and Hyperthermia in Pediatric Patients subsection).

Geriatric Use: Single dose pharmacokinetic parameters are Genamic Use: Single dose pharmacokinetic parameters are similar in elderly and young healthy volunteers (see CUIN-CAL PHARMACOLOGY, Special Populations subsection in full Prescribing Information). Clinical studies of zonisamide did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified subjects. Other reported children experience has not administed differences in responses between the elderly and younger pa-tients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy

ADVERSE REACTIONS

The most commonly observed adverse events associated with the use of ZONEGRAN in controlled clinical trials that were not seen at an equivalent frequency among placebotreated patients were somnolence, anorexia, dizziness, headache, nausea, and agitation/irritability.

In controlled clinical trials, 12% of patients receiving ZONE-GRAN as adjunctive therapy discontinued due to an adverse event compared to 6% receiving placebo. Approximately 21% of the 1,336 patients with epilepsy who received ZONEGRAN in clinical studies discontinued treatment because of an adverse in clinical studies alsocntinued nearmonip associated with dis-event. The adverse events most commonly associated with dis-continuation were somnolence, fatigue and/or atoxia (6%), anorexia (3%), difficulty concentrating (2%), difficulty with memory, mental slowing, nausea/vomiting (2%), and weight loss (1%). Many of these adverse events were dose-related (see WARNINGS and PRECAUTIONS).

Adverse Event Incidence in Controlled Clinical Trials: Table 3 lists treatment-emergent adverse events that occurred in at least 2% of patients treated with ZONEGRAN in controlled clinical triols that were numerically more common in the ZONEGRAN group. In these studies, either ZONEGRAN or placebo was added to the patient's current AED therapy. Adverse events were usually mild or moderate in intensity.

Were usually mild or moderate in intensity. The prescriber should be aware that these figures, obtained when ZONEGRAN was added to concurrent AED therapy, cannot be used to predict the frequency of adverse events in the course of usual medical practice when patient char-acteristics and other factors may differ from those prevailing during clinical studies. Similarly, the cited frequencies cannot be directly compared with figures obtained from other clinical investigations involving different freatments, uses, or investiga-tors. An inspection of these frequencies, however, does provide the prescriber with one basis by which to estimate the relative contribution of drug and non-drug factors to the adverse event contribution of drug and non-drug factors to the adverse event incidences in the population studied.

Table 3. Incidence (%) of Treatment-Emergent Adverse Events in Placebo-Controlled, Add-On Trials (Events that oc-

curred in at least 2% of ZONEGRAN-treated patients and occurred more frequently in ZONEGRAN-treated than placebo-treated patients)

ZONEGRAN (n=269) PLACEBO (n=230)

Concernational and the process of th

Diplopia (6%/3%), Taste Perversion (2%/0%) Other Adverse Events Observed During Clinical Trials: ZONE-GRAN has been administered to 1,598 individuals during all clinical trials, only some of which were placebo-controlled. During these trials, all events were recorded by the investiga-tors using their own terms. To provide a useful estimate of the proportion of individuals having adverse events, similar events have been grouped into a smaller number of standardized cat-egories using a modified COSTART dictionary. The frequencies represent the proportion of the 1,598 individuals exposed to ZONEGRAN who experienced an event on at least one occa-sion. All events are included except those already listed in the previous toble or discussed in WARNINGS or PRECAUTIONS, trivial events, those too general to be informative, and those not reasonably associated with ZONEGRAN.

Events are further classified within each category and listed in order of decreasing frequency as follows: <u>frequent</u> occurring in at least 1:100 patient; <u>infrequent</u> occurring in 1:100 to 1: 1000 patients; <u>rare</u> occurring in fewer than 1:1000 patients.

Body as a Whole: *Frequent:* Accidental injury, asthenia. *Infre-quent:* Chest pain, flank pain, malaise, allergic reaction, face edema, neck rigidity. *Rare:* Lupus erythematosus.

Cardiovascular: Infrequent: Palpitation, tachycardia, vascular insufficiency, hypotension, hyportension, thrombophlebitis, syncope, bradycardia. Rare: Atrial fibrillation, heart failure, pulmonary embolus, ventricular extrasystoles.

punnonar y empoius, ventricular extrasystoles. **Digestive:** *Frequent:* Vomiting. *Infrequent:* Flatulence, gingivitis, gum hyperplasia, gastriis, gastroenteritis, stomatitis, chole-lithiasis, glossitis, melena, rectal hemorrhage, ulcerative sto-matrix, gastro-duodenal ulcer, dysphagia, gum hemorrhage. *Rare:* Cholangitis, hematemesis, cholecystitis, cholestatic jaundice, colitis, duodenitis, esophagitis, fecal incontinence, mouth ulceration.

Hematologic and Lymphatic: Infrequent: Leukopenia, anemia, immunodeficiency, lymphadenopathy. *Rare:* Thrombocytope-nia, microcytic anemia, petechia.

Metabolic and Nutritional: Infrequent: Peripheral edema, weight gain, edema, thirst, dehydration. *Rare:* Hypoglyce-mia, hyponatremia, lactic dehydrogenase increased, SGOT increased, SGPT increased.

Musculoskeletal: Infrequent: Leg cramps, myalgia, myasthenia, arthralgia, arthritis.

Nervous System: Frequent: Tremor, convulsion, abnormal gait, hyperesthesia, incoordination. Infrequent: Hypertonia, twitch-ing, abnormal dreams, vertigo, libido decreased, neuropathy, hyperkinesia, movement disorder, dysarthria, cerebrovascular accident, hypotonia, peripheral neuritis, parathesia, reflexes increased. Rare: Circumoral paresthesia, dyskinesia, dyskonia, acceptalearchy, forsian parachysis, hyperkinesia, buerertheria encephalopathy, facial paralysis, hypokinesia, hyperesthesia, myoclonus, oculogyric crisis.

Behavioral Abnormalities - Non-Psychosis-Related: Infrequent: Euphoria.

Respiratory: *Frequent:* Pharyngitis, cough increased. Infre-quent: Dyspnea. *Rare:* Apnea, hemoptysis.

Skin and Appendages: Frequent: Pruritus. Infrequent: Maculopapular rash, acne, alopecia, dry skin, sweating, eczema, urticaria, hirsutism, pustular rash, vesiculobullous rash.

Special Senses: Frequent: Amblyopia, tinnitus. Infrequent: Con-junctivitis, parosmia, deafness, visual field defect, glaucoma. Rare: Photophobia, iritis.

Urogenital: Infrequent: Urinary frequency, dysuria, urinary incontinence, hematuria, impotence, urinary retention, urinary urgency, amenorrhea, polyuria, nacturia. Rare: Albuminuria, enuresis, bladder pain, bladder calculus, gynecomastia, mastitis, menorrhagia.



Distributed by: Elan Biopharmaceuticals, a business unit of Elan Pharmaceuticals, Inc., a member of the Elan Group, San Diego, CA 92121 ZONEGRAN is a trademark licensed exclusively to Elan Pharmaceuticals, Inc. © 2000, 2003 Elan Pharmaceuticals, Inc.

August 27,2003

https://doi.org/10.1017/S109285290000+9408 Published online by Cambridge University Press

6001061-BS

Printed in the USA